Aurinia can still see growth in product revenues from Lupkynis and has a chance to show that AUR200 has some value in 2025.

The U.S. Food and Drug Administration (FDA) has granted fast track status to ADI-001, Adicet Bio ’s CAR T-cell therapy for ...

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Adicet Bio, Inc. (NASDAQ:ACET), currently trading at $0.99 with a market capitalization of $81.7 million, is a clinical-stage biopharmaceutical company focused on developing novel cell therapies based ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...